FDA approves expanded use of Daklinza in HCV genotypes 1 and 3
8 February 2016 | By Victoria White
The expanded label for Daklinza includes three additional patient populations: HCV patients with HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV...